Ma Xinyi, Song Qingxiang, Gao Xiaoling
Department of Pharmacology and Chemical Biology, Faculty of Basic Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.
Acta Pharm Sin B. 2018 Jan;8(1):51-63. doi: 10.1016/j.apsb.2017.11.006. Epub 2017 Dec 24.
High-density lipoproteins (HDL) are naturally-occurring nanoparticles that are biocompatible, non-immunogenic and completely biodegradable. These endogenous particles can circulate for an extended period of time and transport lipids, proteins and microRNA from donor cells to recipient cells. Based on their intrinsic targeting properties, HDL are regarded as promising drug delivery systems. In order to produce on a large scale and to avoid blood borne pollution, reconstituted high-density lipoproteins (rHDL) possessing the biological properties of HDL have been developed. This review summarizes the biological properties and biomedical applications of rHDL as drug delivery platforms. It focuses on the emerging approaches that have been developed for the generation of biomimetic nanoparticles rHDL to overcome the biological barriers to drug delivery, aiming to provide an alternative, promising avenue for efficient targeting transport of nanomedicine.
高密度脂蛋白（HDL）是天然存在的纳米颗粒，具有生物相容性、非免疫原性且完全可生物降解。这些内源性颗粒能够长时间循环，并将脂质、蛋白质和微小RNA从供体细胞转运至受体细胞。基于其固有的靶向特性，HDL被视为有前景的药物递送系统。为了大规模生产并避免血源性污染，已开发出具有HDL生物学特性的重组高密度脂蛋白（rHDL）。本综述总结了rHDL作为药物递送平台的生物学特性和生物医学应用。它聚焦于为生成仿生纳米颗粒rHDL所开发的新兴方法，以克服药物递送的生物屏障，旨在为纳米药物的高效靶向运输提供一条有前景的替代途径。
